Illumina's net margin has expanded from 20.3% in Q3 2024 to 24.1% in Q4 2025, indicating the company has been successful in driving operational efficiency. During this period, revenue has grown at a robust 16.2% year-over-year rate, demonstrating the company's ability to capitalize on the growing demand for genomic sequencing solutions. This combination of margin expansion and durable revenue growth suggests Illumina is leveraging its market-leading position and technological capabilities to generate attractive returns on invested capital (ROIC), which has improved from 13.8% to 17.2% over the same time frame. The company's free cash flow generation has also been strong, increasing from $293.0M in Q3 2024 to $414.0M in Q4 2025, providing ample financial flexibility to fund growth initiatives and return capital to shareholders. Given Illumina's ability to drive margin expansion, sustain robust revenue growth, and generate healthy free cash flow, I believe the stock presents an attractive investment opportunity. The company's leading market position, innovative product portfolio, and favorable industry tailwinds position it well to continue compounding intrinsic value over the medium to long term. I see Illumina shares reaching $550-$600 (16-25% upside from the current price of $475.92) over the next 12-18 months, as the company's margin profile continues to improve and its revenue growth accelerates further. This target is supported by the company trading at a forward P/E multiple of 25x, which is in line with its high-growth peer group, and a projected ROIC of 19-21% by the end of 2026.

Research these companies